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Original Article
Abstract
Purpose: LY294002, a promising drug for chemotherapy, suppresses the activityof Phosphatidylinositol 3-Kinase (PI3K) which is pivotal to a number of processessuch as proliferation, metabolism, and apoptosis. The compound has, however,been seen to have very variable efficacy in vivo. Methods: Proliferation andviability of two immortalized cells with divergent bioenergetic profiles wasdetermined using crystal violet staining, and the 3-(4, 5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Oxygen consumption rates weredetermined using MitoXpress-Xtra probes, and lactate generation was assessedwith pH-Xtra probe and BM-lactate strips. Immunoblotting was performed withphospho-Akt-Ser 473 and Akt-pan primary antibodies. Results: U87 cells wereshown to have a glycolytic metabolism, whereas RD cells exhibited a more aerobicmetabolism. In both lines, hypoxia was shown to increase lactate production, andLY294002 reduced lactate production. The drug decreased cell proliferation andviability under all conditions, but the effect was greatest in U87 cells undernormoxic conditions. Conclusion: Metabolic analysis showed a link between aglycolytic cell status and LY294002 induced cell death. However, in both cell linesthe drug was also less effective under hypoxic conditions, as would be found in atumour in vivo. Furthermore, in the presence of LY294002 the phosphorylationstatus of Akt, a target of PI3K, was found to be related to both the mechanism of cellrespiration, and the oxygenic status of the cells.
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1. IntroductionLY294002, a quercetin analogue, is recognized as apotent anticancer drug.1 In this study we investigatewhether there is a link between the oxygenic andmetabolic status of the cancer cell and the efficacy ofLY294002. To maintain high proliferative levels cancercells need to re-programme their energy metabolism toallow proliferation under reduced levels of oxygen andnutrients.2 Maintaining growth under hypoxicconditions and evading apoptosis have been stronglylinked to changes in metabolic behaviour.3 Cancer cell
metabolism is very adaptable; switching betweenglycolytic and oxidative phosphorylation dependingupon oncogenic mutation status and the tumormicroenvironment.4LY294002 suppresses the activity ofphosphatidylinositol 3-kinase (PI3K) via competitiveinhibition of an adenosine triphosphate (ATP) bindingsite on the p85a subunit.5 Akt is a well-characterizedeffector of PI3K, and is activated by both translocation to
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the plasma membrane and phosphorylation at Thr 308and Ser 473.6,7 Thr 308 phosphorylation (byphosphoinositide-dependent kinase-1; PDK1) isnecessary and sufficient for Akt activation but maximalactivation requires additional phosphorylation at Ser473.8 The PI3K/Akt pathway exhibits control overproliferation, migration, metastasis, metabolism,apoptosis, and angiogenesis, and is therefore a target foranticancer agents.1The metabolic profiles of cells are affected by the oxygenand glucose concentration of their environment, withcells on the periphery of tumors growing more quicklythan those in the centre.9,10 The Warburg model statesthat cancer cells use higher levels of glucose than normalcells, and show increased lactate generation. However,this may not be a universal truth for all cancers, andcould have implications for therapeutics which targetcancer cell metabolism.11 Herein, we have thereforeassessed the effect of LY294002 under normoxic andhypoxic conditions and in cell lines with differentmetabolic profiles.
2. Methods and Materials
2.1. Cell cultureCells were plated at a density of 1 × 104 cells per well(96-well plate, Nunc) in 200 μL of growth medium(Dulbecco's Modified Eagle's Medium (DMEM))including 25 mM glucose, 1 mM pyruvate [Sigma]),supplemented with 10% foetal bovine serum [Sigma], 2mM L-Glutamine [Gibco], 100Ū/mL Penicillin and 0.1mg/mL Streptomycin [Gibco]) in 96-well plates andincubated at 37 °C in 5% CO2 atmosphere. Cells grownunder hypoxic conditions were incubated in 1% O2 and5% CO2.Two cell lines, U87 (American Type Tissue CultureCollection (ATCC) number HTB14, glioblastomaastrocytoma) and RD (ATCC number CRL-7763,rhabdomyosarcoma), were selected on the basis of theirvery different metabolic phenotypes in vitro whencultured on different concentrations of glucose. The RDcell line shows a consistently high level of oxidativephosphorylation on both high (25 mM) and low glucosemedia (1 mM) while U87 shows a low level of oxidativephosphorylation on high glucose which can besignificantly increased by growth on low glucose media.9Both cell lines show reduced media acidification/ lactateproduction on 1mM glucose.
2.2. Crystal violet assayCell number was assessed using crystal violet (CV)staining. CV is a triphenylmethane dye whichintercalates with DNA in a similar manner to ethidiumbromide but is less mutagenic and detectable in thevisible range. CV staining therefore provides a simplemethod for obtaining quantitative data on the number ofcells based on the absorbance of the dye by DNA in the
cells. Cells were rinsed with pre-warmed PBS and fixedwith 1% glutaraldehyde solution for 30 min. Fixed cellswere stained with crystal violet solution (1% crystalviolet [Sigma] dissolved in a mixture of methanol: glacialacetic acid: H2O, 5:1:4 v/v/v) for 1 hour at roomtemperature. After staining, the supernatant wasremoved and cells washed carefully three times withwater. The plate was then drained and dried overnight.Before reading, 100 µL solubiliser (1% sodium dodecylsulfate in 10% glacial acetic acid) was added to each welland resuspended vigorously. The absorbance was readat 540 nm.
2.3. MTT assayMTT is a colorimetric assay based on the capacity of thecellular mitochondrial dehydrogenase in living cells toreduce the yellow water-soluble substrate 3-(4,5-dimethylthiazol-2yl)-2, 5-diphenyl tetrazoliumbromide (MTT) into a dark blue/purple formazanproduct which is insoluble in water. Cells were washedtwice with pre-warmed PBS and 100 µL 0.5 mg/mL MTTsolution (0.5 mg/mL dissolved in a mixture of phosphatebuffered saline (PBS): growth medium, 1:9 v/v) wasadded to each well and incubated at 37 oC, in darkness.After 4 hours incubation the supernatant was removedand the MTT solubilized with 100 µL dimethyl sulfoxideper well. The absorbance was read at 570 nm.
2.4. Extracellular pH assayThe phosphorescence of pH-Xtra probe [LuxcelBiosciences] increases as lactic acid is produced and themedia pH decreases. The pH–Xtra probe provides dataon the rate at which pyruvate is converted to lactic acidwith changes in fluorescence linked to the glycolyticactivity of cells. The assay was carried out on cellsincubated in clear bottom black tissue culture plates (BDfalcon) and carried out according to manufacturers’instructions. The buffer solution was modified from thestandard method to remove the potassium phosphate(20 mM glucose, 70 mM NaCl, 50 mM KCl, 0.8 mMMgSO4, and 2.4 mM CaCl2; pH7.4). Changes in timeresolved fluorescence are monitored in a BMG Omegaplate reader, using filters TR-exl (excitation) and 615 nm(emission). The lifetime is measured using dual delaytime resolved measurements. The delay times forpH-Xtra are 100 and 300 μsec. The raw data produced isa graph of time (x-axis) versus TR-F intensity (y-axis).These measured TR-F intensity signals need to beconverted into phosphorescence lifetime values. This isperformed using the following equation:Lifetime τ (µs) = ( )Here t2 – t1 is delay time which is set to 200 µs, D1 andD2 are measured intensity value at time point t1 and t2.Once the lifetime curves have been calculated it ispossible to determine the extracellular acidification rate
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of the samples by looking at the difference in the lifetimevalues (rate of change) between two set time points.Extracellular acidification rates (ECAR) are calculatedfrom the linear part of the assay before a plateau isreached.
2.5. Lactate assayLactate generation was evaluated with BM-lactate strips[Roche]. For each sample, 25 µL media was added on tothe reactive pad of a new lactate strip. The result wasread by an Accutrend Lactate Meter [Roche] afterincubation for 1 min.
2.6. ImmunoblottingTreated cells were lysed with tissue extraction buffer(50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mMethylenediaminetetraacetic acid (EDTA), 1% TritonX-100, 0.1% sodium dodecyl sulfate (SDS), add 1 tabletof protease inhibitor in every 10 mL buffer before use).The lysates were quantified with the Pierce BCA proteinassay kit (Thermo Scientific), mixed with loading buffer(Invitrogen) and reduced buffer (Invitrogen), and heatedto 95 oC for 5 min before being analyzed by sodiumdodecyl sulfate polyacrylamide gel electrophoresis(SDS-PAGE; 8-16% Precise Protein Gel; ThermoScientific). Gels were transferred to nitrocellulose paper(Amersham) in transfer buffer (200 mM Glycine, 25 mMTris, 20% Methanol) at 100 V for 1 hour. Membraneswere blocked in Tris-buffered saline with 0.1% Tween20 (TBST) containing 5% powdered milk at 4 oCovernight.After washing with TBST buffer, membranes wereincubated for 1 hour at 4 ºoC with primary antibodies;Phospho-Akt-Ser473 (pAkt-ser473, Cell Signaling), andAkt (pan) (Cell Signaling). The appropriateHRP-conjugated secondary antibody (Invitrogen) wasused and the proteins on membranes were detectedusing the ECL Western Blotting Analysis System(Amersham) and autoradiography film (Hyperfilm ECLfrom Amersham Biosciences).The band intensity on immunoblots was quantifiedusing Image J software. On each blot, the density of bothpAkt-ser473 and Akt (pan) were divided by the densityof the house-keeping protein -actin. Samples were thennormalized against -actin. Values are expressed as % ofthe zero drug control.
2.7. Statistical analysisWhere data is presented as an average value, error barsare shown as standard deviation of the mean. Data wasanalysed by the one–tailed student t-test: one star (*) forp values ≤ 0.05, two stars (**) for p values ≤ 0.01,and three stars (***) for p values ≤ 0.001.
3. Results
3.1. Immortalized cancer cell lines have different
bioenergetics profilesImmortalized cancer cell lines vary greatly in theirbioenergetics profiles. We have previously measured theoxygen consumption rate (OCR) and extracellularacidification rate (ECAR) for a number of cell lines, inorder to quantify mitochondrial respiration, and to givean indication of glycolysis.9 For this study we thereforechose to look at the response of two bio energeticallydifferent cell lines at the extremes of our OCR v ECARmetabolic analysis; an aerobic line (RD) and a glycolyticline (U87).The U87 and RD cell lines were subjected to NextGeneration Sequence analysis of hotspot regions of 50oncogenes and tumor suppressor genes (SupplementaryTable 1). The metabolic status of the two chosen lineswas further characterized by 13C-NMR (SupplementaryFigure 2).
3.2. The reduction in cell proliferation caused by
LY294002 is much less marked under hypoxic
conditionsCells were incubated with LY294002 at micromolarconcentrations up to 50 µM in RD and U87 cells. Theefficacy of the LY294002 drug in reducing cellproliferation was assessed using the CV assay. RD cellsincubated with LY294002 under normoxic conditionsshowed a decrease in cell number with increasing drugdose, and at the maximum dose of 50 M the drug can beseen to reduce cell proliferation by approximately 27.0% ± 3.2 (Figure 1a). U87 cells showed a more dramaticresponse to LY294002 under the same conditions,showing approximately 61.3% ± 1.3 decrease in cellproliferation at 50 M drug (Figure 1b). Both reductionsin cell number were shown to be statistically significant.Under hypoxic (1% O2) conditions and incubation with50 M LY294002 RD cells showed a reduction of only13.4% ± 5.2 (Figure 1a), while under the sameconditions U87 cells showed a reduction of 17.5% ±12.5, although neither reduction was statisticallysignificant (Figure 1b).Therefore the two cell lines show both differentsensitivity to the drug and altered sensitivity underreduced oxygen conditions. The fact that both cell lineswere less susceptible to the drug under the hypoxicconditions underlines the importance of using testconditions that are as close as possible to the in vivoconditions.
In addition to determining proliferation, the viability ofcells treated with LY294002 was assessed using theMTT assay. RD cells showed a reduction in metabolic
4 Huang et al.: Quercetin analogue LY294002 in immortalized cancer cell lines International Journal of Cancer Therapy and Oncology
www.ijcto.org
© Huang et al. ISSN 2330-4049
activity of 23.1% ± 4.3 under normoxic conditions, andan 11.1% ± 1.5 reduction in metabolism under hypoxicconditions, when incubated with 50 M LY294002(Figure 2a). U87 cells demonstrated a much moremarked reduction in metabolism under normoxicconditions, with a reduction of 72.4 % ± 2.6 compared tocontrol. Under hypoxic conditions, cells were much lessaffected with a reduction in metabolism of 30.9 % ± 4.0(Figure 2b). Hence, the same trend is seen in terms ofboth proliferation and metabolism of cells.
3.3. Lactate production under both normoxic and
hypoxic conditions, is decreased by LY294002Levels of lactate, an established product of glycolysis,were determined in the culture media of RD and U87cells under both normoxic and hypoxic conditions(Figure 3). Under both normoxic and hypoxic conditions
RD cells generated considerably less lactate than U87cells. Under hypoxic conditions lactate levels increasedin RD cells, but not U87 cells.The addition of drug showed significant reductions inlactate generation for both cell lines under bothnormoxic and hypoxic conditions. Under normoxicconditions the drug reduced lactate in RD cells toundetectable levels, and U87 cells showed a 55.70 % ±0.08 reductions compared to control levels (Figure 3).Under hypoxia, RD cells showed a 42.76 ± 0.04%reduction and U87 cells 66.00 ± 0.03% reduction inlactate concentration compared to normoxic levels(Figure 3). These results would be consistent with aslowing of glycolysis which would be expected if thePI3K pathway were inhibited by LY294002.
Figure 1: Cell number assessed using crystal violet staining, in the presence of increasing concentrations of LY294002,under either 1% or 21% oxygen, after incubation for 24 hours (a) RD cells (b) U87 cells. Figure shows a representativeresult of independent experiments, herein n=3, ± standard deviation (SD) mean. Significance was determined by theone-tailed student t-test.
Figure 2: Cell metabolism assessed using MTT assay, in the presence of increasing concentrations of LY294002, eitherunder 1% or 21% oxygen, after incubation for 24 hours (a) RD cells (b) U87 cells. Figure shows a representative resultof independent experiments, herein n = 3 for each variable, ± SD mean. Significance was determined by the one-tailedstudent t-test.
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Figure 3: Lactate detected in the culture medium after 24 hours in the presence and absence of LY294002 for RD andU87 cells under 1% and 21% oxygen. The results were calibrated with relative cell number. (Using Student's t test, ***P < 0.001; the data are presented as the means ± standard deviation, n = 3)
Figure 4: (a) Representative immunoblot of cell lysates from cells incubated with increasing amounts of LY294002under either 1% O2 or 21% O2 (i) RD cells (ii) U87 cells. Blots were probed with anti-Akt (pan) or anti-pAkt-ser473antibodies (b) Densitometry data taken from immunoblots shown in panel ‘a’.
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3.4. Phosphorylation status of Akt in the presence
of LY294002 depends on both metabolic and
oxygenic status of the cellsLY294002 acts upon PI3K and consequently affects thephosphorylation status of the downstream target, Akt.Akt is activated by phosphorylation within the carboxyterminus at Ser473 and by phospholipid binding andactivation loop phosphorylation at Thr308 by PDK1.12We therefore investigated the phosphorylation status ofAkt from cell lysates collected from both RD and U87 celllines under either hypoxic or normoxic conditions, andin the presence of increasing concentrations ofLY294002. RD cells showed a decrease inphosphorylation of Akt at Ser473 under normoxic (21%oxygen) conditions (Figure 4a; i). Phosphorylation of Aktcould be seen to decrease to approximately 15.4% ofzero drug control (Figure 4b). However, under hypoxicconditions (1% oxygen) the protein can be seen to bephosphorylated even in the presence of 50 µM drug(Figure 4a; i), equivalent to 59.8% of control (Figure4b).Therefore, the pathway is not being inhibited byLY294002, consistent with higher cell viability as seen inRD cells under hypoxic conditions (Figure 4b).Conversely, U87 cells showed a decrease in thephosphorylation of Ser 473 under both normoxic andhypoxic conditions (Figure 4a; ii). Under hypoxicconditions at 50 µM, phosphorylation falls to 38.1% ofcontrol, whereas under normoxic conditionsphosphorylation is even further reduced to 13.6% ofcontrol.Thus, the higher level of AKT phosphorylation followingLY294002 treatment in RD cells under hypoxicconditions is aligned with the higher cell viability of thiscell line. This suggests that LY294002 may be lesseffective under hypoxic conditions in cells with apredominantly oxidative phosphorylation (OXPHOS)mechanism.
4. DiscussionIt is highly likely that the metabolic profile of cancercells and substrate availability (e.g. glucose and oxygen)will have a major effect on the growth of cancers in vivoand the efficacy of drugs used to treat them. Recent in
vivo studies have identified glycolytic and OXPHOS subgroups of cancer cells in a variety of cancers includingBrain13, Lymphoma14 and Liver15. We have previouslyestablished the base-line bioenergetics phenotype of anumber of human cancer cell lines9 and used this data tochoose a more aerobic (RD) and glycolytic (U87) cell lineto study with LY294002 (see also supplementaryinformation for 13C NMR data). This was in agreementwith other reports, where U87 cells were shown toexhibit a glycolytic-dependent phenotype withfunctional OXPHOS.16 We therefore investigate theeffects of reduced oxygen availability on drug treatmentin these two metabolically diverse cell lines.
Low oxygen tension in tumors has also been associatedwith increased metastasis and poor survival inpatients.17,18 Such conditions may also affect the ways inwhich chemotherapy drugs act on the cells. Wetherefore wanted to assess the proliferation rate of cellsin the presence of the drug, under both normoxic andhypoxic conditions (1% O2). To ensure that the drugitself was not altered under the experimental system,the compound was first monitored by 1H NMRspectroscopy under a variety of conditions: The drugwas dissolved in methanol and monitored after 1 hour,24 hours, 3 days, 7 days and 28 days; the solution wasexposed to UV light for 24 hours, and the drug wasdissolved in ethanol: PBS (1:3.5) for 24 hours with orwithout UV exposure, and under 1% oxygen in bothsolvent systems. We were able to confirm that none ofthe conditions resulted in a change to the molecule asmonitored by NMR spectroscopy (data not shown).Experiments were performed with LY294002 at micromolar concentrations up to 50 µM. This is in line withother studies; for example Lee et al.,19 treated threedifferent hepatocellular carcinoma lines and showedsuppressed cell growth with 40 µM LY294002, andBuotempo et al.,20 showed radio-sensitization of twocervical cancer lines with 25 µM LY294002. Datashowed that under normoxic conditions, cell death asdetermined by proliferation was dose-dependent in bothcell lines, although U87 cells were more susceptible tothe drug. As well as determining proliferation, theviability of cells treated with LY294002 was alsoassessed using MTT since reduction of the dye onlyoccurs in metabolically active cells and marked changesin metabolic activity can potentially result in significantchanges in results despite the fact that the number ofviable cells remains constant.21 Our study, however,confirmed that the same trend was seen in terms of bothproliferation and metabolic activity, in both RD and U87cells. From our data it can be seen that not only do thetwo cell lines tested show different sensitivity to thedrug, but the sensitivity is altered under reduced oxygenconditions. The fact that both cell lines were lesssusceptible to the drug under hypoxic conditionsunderlines the importance of using test conditions thatare as close as possible to the in vivo conditions. This isimportant in vivo since cancerous tissue is often hypoxicdue to limited angiogenesis which can compromisenormal biological functions.22It has been proposed that increased rates of glucosemetabolism in tumor cells are associated with Akthyperactivation.23,24 LY294002 acts upon PI3K andconsequently affects the phosphorylation status of Aktas a downstream target. These observations have led tothe proposal that inhibition of Akt signaling wouldinhibit glycolysis and increase hydrogen peroxideproduction which would preferentially kill tumor cellsversus normal cells via oxidative stress.25
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Phosphorylation of Akt at Ser 473 in RD cells showedless of a decrease in phosphorylation under bothnormoxic and hypoxic conditions, than U87. Thus, thehigher level of AKT phosphorylation followingLY294002 treatment in RD cells under hypoxicconditions is aligned with the higher cell viability of thiscell line. This again suggests that LY294002 may be lesseffective under hypoxic conditions in cells with apredominantly OXPHOS mechanism. Our results areconsistent with the hypothesis that a slowing ofglycolysis would be expected if the PI3K pathway isinhibited by LY294002. Furthermore, PI3K is adownstream signal mediator of the insulin receptor thatactivates translocation of the glucose transporterGLUT4, to the cell surface and LY294002 has beenreported to reduce levels of the glycolytic enzymespyruvate kinase M1/M2, fructose-biphosphate aldose A,phosphoglycerate kinase 1, triose phosphate isomerase,and alpha enolase.26To further interrogate the effects on metabolism in thepresence of LY294002, the generation of lactate by cells
in vitro was assessed. Our data indicates that theaddition of drug showed significant reductions in lactategeneration for the two cell lines under both hypoxic andnormoxic conditions. This is in agreement with aprevious study in LN18 glioblastoma cells which showedthat the presence of the inhibitor LY294002 abolishedAkt phosphorylation, and concomitantly inhibitedglucose uptake and lactate production.27Although sourced from two different tumor types (U87,adult glioblastoma; RD, paediatric rhabdomyosarcoma)an oncogene screen (Supplementary Figure 2, andSupplementary Table 1) could potentially highlightdifferences which could be explored in future studiesinvestigating larger cancer panels. Mutations wereidentified in PTEN 209 G → T in the U87 line and TP53742 C → T in the RD line (Supplementary Table 2 and 3).Common mutations in the tumor suppressor genes TP53and PTEN are strongly linked to cellular responses tometabolic energy stress, and the regulation of bothglycolysis and oxidative phosphorylation.28,29 Mutationsin both TP53 and PTEN could also affect drugsusceptibility with the PTEN mutation in the U87 cellline likely having an impact on susceptibility to PI3Kinhibitors.30 Other mutations that were identifiedinclude an NRAS 183 A → T (RD) and a CDKN2A deletion(U87) (Supplementary Table 2). The NRAS mutation inthe RD line could be linked to its reduced sensitivity toLY294002 and its high level of mitochondrialrespiration. KRAS mutations have been shown able tounregulated glucose uptake when glycolysis isinhibited31 and maintain high levels of mitochondrialoxidative metabolism.32,33 Mutations in cyclin dependentkinases such as CDKN2A although linked to uncontrolledproliferation are unlikely to be linked to differences inmetabolism and responses to PI3K inhibitors.
5. ConclusionIn conclusion, the drug can be seen to have affected thetwo cell lines tested to dramatically different extents.Metabolic profiling to determine which cells in vivo willbe treatable by a drug is likely to become increasinglyimportant. Tumors in vivo appear to be heterogeneous interms of their energy metabolism, with cancer cellsusing both glycolysis and oxidative phosphorylation. Intime it is possible that bioenergetics profiling of tumorsfrom biopsy materials will enable drugs, andcombinations of drugs, to be specifically selected for aparticular cancer type or group of patients.
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SUPPLEMENTARY INFORMATION
1. Methods and Materials
1.1. Nuclear magnetic resonance spectroscopy (NMR)Cells were fed with DMEM supplemented with 2 mM L-glutamine, 1 mM pyruvate and 20 mM D-[U-13C] glucose (UKIsotope) for 2 hours. After 2 hours cells were washed with ice cold PBS. Cells were then scraped over dry ice andextracted with a 55:35:10 mix of MeCN: MeOH: double distilled H2O. Samples were vortexes, centrifuged and thesupernatant freeze dried. Lyophilised products were reconstituted in 50mM sodium phosphate buffer (pH 7)containing 500 µM TSP, 1.5 mM sodium azide and 10% D2O (Sigma).
13C NMR spectra were collected on a Bruker AVIII 700 spectrometer equipped with a He-cooled TCI cryoprobe withsample temperatures stabilized at 298K in 5 mm NMR tubes. Pulse excitation used a 3.6 µs ( 30o) 13C pulse and powergated proton decoupling was achieved with a WALTZ-16 scheme employing 80 µs 1H 90o pulses during the 0.8 sacquisition period. Data accumulations consisted of between 2000 - 10240 transients per 1D spectrum. All spectrawere processed using a 1Hz exponential line broadening (LB = 1 Hz).
1.2. Next Generation sequencingNext Generation Sequencing (NGS) analysis was performed on 50 known oncogene and tumor suppressor genes.Analysis was carried out by NIM Genetics (Madrid) and involved an initial enrichment, by multiplex PCR, of selectedregions of oncogenes and tumor suppressor genes which make up the lon AmpliSeqTM HotSpot Cancer Panel v2 (FigureS1). NGS of the enriched sample, and subsequent data analysis, were performed to identify mutations affecting theseregions, with specific attention to 2855 hotspot mutation sites. NGS was carried out using the ION Torrent PersonalGenome Machine (Life Technologies). The obtained reads were then aligned to the Human genome (build 37hg19)using the TMAP aligner v.3.63-1 (Life Technologies). Variants were called using Variant Caller v.3.6.59049 (LifeTechnologies). Briefly, aligned sequences were filtered based on quality and mapping scores before being analyzed fordifferences between the obtained sequence and the reference sequence. The variant calls were further evaluated usingthe following databases: dbSNP the 1000 genomes project, and the Exome Variant Server. This showed whether agiven variant is present in the general population at polymorphic frequencies (1% or greater) and has not beenassociated with disease. The COSMIC database was then consulted to annotate any variants that were called in thesamples and found in the database. Finally, each variant was analysed using the Variant Effect Predictor and PROVEANtools to establish the predicted biological effect. Splice site statistical analysis was performed using ALAMUT(Interactive-Biosoftware). The sequencing panel has been designed to specifically target mutational hotspots that arefrequently mutated in human cancers. Mutations at other sites in the 207 amplicons may not be detected with thesame level of sensitivity. The target genes are not sequenced in their entirety and therefore mutations that are notpresent in the sequenced regions will not be detected. The limit of somatic mutation detection is 5% at a depth ofcoverage of 500x.
1.3. Synthesis route for LY294002Step (i): 3-phenyl salicaldehyde (2)
(2) was synthesized from commercially available 2-phenyl phenol (1) by ortho-formylation (Hoffsloken & Skattebol,1999). To solution (0.20 M) of (1) 1 eqv. in dried THF was added Et3N (2 eqv.), MgCl2 (2 eqv.) and paraformaldehyde(5 eqv.) respectively. The reaction mixture was stirred for 2 hours, reflux at 70 °C. NMR of crude showed 90% or moreconversion. Crude was subjected to step 2 without purification.Step (ii): 3-phenyl salicylic acid (3)
(3) was an oxidation product of (2) from Pinnick-like oxidation (Kang et al., 2003). To solution of (2) (1 eqv., 1.16 g,5.86 mmol) in dimethyl sufoxide (17.8 mL) was added NaH2PO4(aq) (2.5 eqv., 1.64 g) and NaClO2(aq) (2.5 eqv. , 1.32 g)at 0 °C. The reaction mixture was slowly warmed up to room temperature and stirred overnight then additional
OH
COOH
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NaH2PO4(aq) (1 eqv., 703 mg) and NaClO2(aq) (1 eqv., 523 mg) were added at 0 °C and stirred overnight. The reactionmixture was acidified by 1 M HCl and was extracted by ethyl acetate. The organic layer was dried over NaSO4(s),filtered and solvent was removed under vacuum. Column chromatography (gradient, 3:1:0.1 = petroleum ether : ethylacetate : acetic acid) of the concentrated crude resulted off-white solid (476 mg, 41% yield) m.p. 186 - 188 °C Meltingpoint was consistent with those previously reported (Brooks et al., 1961). No NMR spectra have been published.Step (iii): methyl 2-hydroxy-[1,1'-biphenyl]-3-carboxylate (4)
Ester (4) was synthesized from (3) by esterification. To solution of (3) ( 476 mg, 2.22 mmol) in anhydrous methanol(156 mL) was added H2SO4 (15.6 mL). The reaction mixture was stirred and heated to reflux at 85 °C for two days. Thereaction mixture was then cooled to room temperature before neutralized by NaH2CO3(aq) (2.9 - 3.5 M) and wasextracted by ethyl acetate. The extract was dried over NaSO4(s), filtered and solvent was removed under vacuum toafford colorless oil which crystallizes upon standing (453 mg 1.98 mmol, 89.4% yield).Step (iv): 1-(2-hydroxy-[1,1'-biphenyl]-3-yl)-3-morpholinopropane-1,3-dione (5)
(5) was synthesized from (4) by claisen-like reaction (Griffin et al., 2005). Dried tetrahydrofuran (3 mL) was added 18M lithium, diisopropylamide (0.42 mL) and 4-acetylmorpholine (43.9 µL). The reaction mixture was stirred at roomtemperature for 30 minutes before addition of solution of (4) (54.1 mg) in dried tetrahydrofuran (3 mL). The reactionmixture was left to stir at room temperature overnight. The reaction mixture was neutralized by 1 M HCl and wasextracted by CH2Cl2. The extract was dried over NaSO4(s), filtered and solvent was removed under vacuum to affordyellow oil. The concentrated crude was purified by column chromatography to give off-white solid (5) (49.3 mg, 64%yield) 1H NMR (250 MHz, CDCl3) : 12.44 (1 H, s), 7.88 (1 H, dd, 7.9, 1.8), 7.54 - 7.60 (3 H, m), 7.33 - 7.48 (3 H, m), 7.02(1 H, t, J 7.8), 4.18 (2 H, s), 3.72-3.68 (6 H, m), 3.56 - 3.51 (2 H, m) 13C NMR (CDCl3) δc: 200, 164.8, 160.1 138.0, 136.6,131.4, 130.2, 129.3, 128.2, 127.5, 119.2, 119.1, 66.7, 66.5, 47.0, 45.5, 42.4. 1H NMR data was consistent with thosepreviously reported4 no data about 13C NMR previously reported.Step (v): 2-morpholino-8-phenyl-4H-chromen-4-one (6)
(6) was obtained from (5) by cyclodehydration (Zhou et al., 2008). To solution of (5) (49.3 mg, 0.15 mmol) in driedCH2Cl2 (0.75 mL) was added triflic anhydride (91.8 µL). The reaction mixture was stirred overnight then concentratedunder vacuum. Anhydrous methanol (10 mL) was added to reaction mixture and was stirred for 4 hours. The reactionmixture was neutralized by NaHCO3(aq) and extracted by CH2Cl2. The organic layer was dried over Na2SO4(s), filteredand solvent was removed under vacuum. The crude reaction mixture was purified by column chromatography to giveoff-white solid (6) (25.3 mg, 55% yield) ) 1H NMR (500 MHz, CDCl3) : 8.17 (1 H, dd, J 7.9, 1.6), 7.56 (1 H, dd, J 7.3,1.6), 7.51-7.38 (6 H, m), 5.50 (1 H, s), 3.71 (2 H, t, J 4.9), 3.3 (3 H, t, J 4.8) 13C NMR (500 MHz,CDCl3) δC: 177.2, 162.5,150.5, 136.3, 133.4, 130.3, 129.3, 128.3, 128.0, 125.0, 124.7, 123.3, 87.0, 65.9, 44.7.
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2. Results
2.1. 13C-NMR studiesThe metabolic status of the two chosen cell lines was characterized by 13C-NMR. Figure S1 illustrates the potential fateof universally labeled glucose, depicting how it is metabolized through the glycolytic pathway to lactate or throughpyruvate into the TCA cycle. Glycolysis will produce pyruvate and lactate molecules that are labeled in all three-carbonpositions. If the TCA cycle is functioning normally (active PDH), then after the first cycle glutamine and glutamatedoublets labeled in the 4-5 position can be seen. This labeling can only occur if PDH and the TCA cycle result in glucoseoxidation via the mitochondria. As the TCA cycle completes further cycles other multiplet labeling patterns are seen (in3, 4 and 5 carbon positions) and evidence of complete turnover of the cycle is confirmed by double doublets (quartets)in glutamine and glutamate C4 position.17The addition of U-13C glucose to U87 (glycolytic) and RD (aerobic) cell extracts revealed many similarities between thetwo cell lines with spectra showing multiple peaks of 13C labeled metabolites. Close examination of the spectra showedthat there was significant TCA cycle activity in both cell lines. The NMR spectra show glutamate 4-5 doublets in bothU87 and RD cell lines. The U87 extract also shows double doublets (Q435) which are generated from completeturnover of the TCA cycle. To the contrary, the RD extract contained the doublets but not the quartets; the reason forthis is still unknown. Glutamine labeling was also observed and was similar for both lines (data not shown). Largelactate peaks were seen for the U87 but also for the RD cell line, which had shown a more aerobic energy profile(Supplementary Figures 1 b&c). As internal standards were not used in these experiments the concentrations of lactatecannot be quantified with peak sizes only giving relative amounts. The lactate peaks in the RD extracts were a littleunexpected given their aerobic nature and low levels of lactate production (Figure 3).
Supplementary Figure S1: (a) Schematic depicting the possible fate of U13 C labeled glucose in the cell; adapted fromMarin Valencia et al., 2012 (b) Whole 1D-NMR spectrum of U13C labeled glucose metabolites in U87 and RD cells; inlayshows glutamate metabolites in more detail (c) Higher resolution spectra of Glutamate C2, C3 and C4 metabolites.The U87 glioblastoma cell line showed a significant amount of glucose oxidation. However, this oxidation is not linkedto respiratory chain ATP production. It is possible that U87 cells generate high levels of lactate due to an increase inglycolysis linked to the inability to couple TCA cycle activity to mitochondrial respiration. The metabolomics datacoupled with the data from the metabolic assays suggests that both glycolysis and glucose oxidation are equallyimportant for U87 cells; glycolysis perhaps providing ATP, and glucose oxidation providing intermediates formacromolecule synthesis. While the mitochondria in U87 cells are not being utilized for energy it is clear that they areactive in their TCA cycling, presumably as a means of meeting the biosynthetic demands required to provideaccelerated growth.28The glycolytic rate in RD cells appears lower than U87 but energy production via mitochondrialrespiration appears more efficient. RD cells with higher levels of mitochondrial respiration could potentially use other
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substrates (i.e. fatty acids and glutamate) to generate ATP if glycolysis is impaired. Under hypoxic conditions with highconcentration of glucose (20 mM), the RD cell line will likely be more impaired than the U87 cell line as it appearsreliant on mitochondrial respiration. The U87 line with its high level of glycolysis might show very little effects ofhypoxic growth. A compound which inhibits glycolysis is likely to have a significant effect on the U87 cells undernormoxic conditions as these cells appear reliant on high rates of glycolysis to generate ATP.
2.2. Gene sequencingThe sequencing libraries generated from the U87 and RD cell lines were sequenced to an average depth of 3023 and3398 respectively, resulting in 97.42% and 97.05% of bases included in the panel being sequenced to a depth of atleast 500x. In the U87 cell line one hot spot mutation was identified in the PTEN gene (Supplementary Table 2).
Supplementary Table S1: List of the 50 oncogenes and tumor suppressor genes included in the Ion AmpliSeq TMHotSpot cancer panel v2
Supplementary Table S2: Non-polymorphic changes identified in cell lines U87 and RD. The reference allele (Ref.Allele) and variant allele are both listed in the table. “Var. Freq.” refers to the variant frequency in the sequenced reads,which is representative of the population of cells sequenced. “Cov” refers to the sequence coverage i.e. the number oftimes the position has been sequenced. A splice site variant was identified in the U87 cell line and two missensemutations in the RD line. The RD line mutations are present in the COSMIC database and their COSMIC IDs are includedin the table.This mutation at C209 G > T is located in the intron 3 splice site of the PTEN gene. An in-silico prediction of splicing wasperformed using the available algorithms (SSF, MaxEnt, NNSPLICE, GeneSplicer and HSF) in ALAMUT(Interactive-Biosoftware, Rouen, France).
Supplementary Figure S2: Coverage overview plots of sample (a) U87, and (b) RD. An absence of coverage inchromosome 9 indicates a homozygous deletion in U87 but due to the design of the sequencing experiment it is not
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possible to identify the coordinates of the breakpoints. The IGV image (c) shows sequencing reads from the same twosamples in the affected exon 3 of CDKN2A. No sequencing reads are observed in sample U87.A significant change in the donor site is predicted (Supplementary Table 3). In addition coverage analysis performedon the sequencing results showed a lack of coverage of chromosome 9 for the U87 sample (Supplementary Figure 2a).
Supplementary Table S3: Results of splice site analysis, performed in Alamut. Four algorithms were used to evaluatethe effect of the c209 + 1 G → T mutation. Analysis with SSF, MaxEnt, NNSPLICE and HSF all predicted a deleteriouseffect on splicing. Ranges of possible values are in square brackets and the significance thresholds can be found initalics. Values greater than the threshold predict a deleterious effect.This was confirmed visually in IGV and affects the CDKN2A gene (Supplementary Figure 2c). This is most likely causedby a homozygous deletion in the region however due to the design of the sequencing experiment it is not possible toidentify the coordinates of the break point.
